Dermatitis, psoriasis candidate passed from GSK to Dermavant

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) will shell out £150 million ($200 million) up front to GlaxoSmithKline plc

Read the full 232 word article

User Sign In